Literature DB >> 17875191

Serious haematological toxicity of cyclophosphamide in relation to CYP2B6, GSTA1 and GSTP1 polymorphisms.

Agnès Tran, François Bournerias, Christine Le Beller, Olivier Mir, Elisabeth Rey, Gérard Pons, Michel Delahousse, Jean-Marc Tréluyer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17875191      PMCID： PMC2291223          DOI： 10.1111/j.1365-2125.2007.03020.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  6 in total

1.  Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19.

Authors:  R Timm; R Kaiser; J Lötsch; U Heider; O Sezer; K Weisz; M Montemurro; I Roots; I Cascorbi
Journal:  Pharmacogenomics J       Date:  2005       Impact factor: 3.550

2.  Pharmacogenetics of cyclophosphamide in patients with hematological malignancies.

Authors:  Hanjing Xie; Laimonas Griskevicius; Lars Ståhle; Zuzana Hassan; Umit Yasar; Anders Rane; Ulrika Broberg; Eva Kimby; Moustapha Hassan
Journal:  Eur J Pharm Sci       Date:  2005-09-23       Impact factor: 4.384

3.  Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment.

Authors:  Carol Sweeney; Christine B Ambrosone; Lija Joseph; Angie Stone; Laura F Hutchins; Fred F Kadlubar; Brian F Coles
Journal:  Int J Cancer       Date:  2003-03-01       Impact factor: 7.396

4.  Allelic variants of the human glutathione S-transferase P1 gene confer differential cytoprotection against anticancer agents in Escherichia coli.

Authors:  Tricia M Ishimoto; Francis Ali-Osman
Journal:  Pharmacogenetics       Date:  2002-10

5.  Reversal of multiple drug resistance in cholangiocarcinoma by the glutathione S-transferase-pi-specific inhibitor O1-hexadecyl-gamma-glutamyl-S-benzylcysteinyl-D-phenylglycine ethylester.

Authors:  Takaharu Nakajima; Tetsuji Takayama; Koji Miyanishi; Atsushi Nobuoka; Tsuyoshi Hayashi; Tomoyuki Abe; Junji Kato; Kiyoyuki Sakon; Yoshimitsu Naniwa; Hirohumi Tanabe; Yoshiro Niitsu
Journal:  J Pharmacol Exp Ther       Date:  2003-06-12       Impact factor: 4.030

Review 6.  Clinical pharmacokinetics of cyclophosphamide.

Authors:  Milly E de Jonge; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577
  6 in total
  3 in total

1.  Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients.

Authors:  Nasir Ali Afsar; Mike Ufer; Sierk Haenisch; Cornelia Remmler; Ahmed Mateen; Ahmed Usman; Khwaja Zafar Ahmed; Hakimuddin Razi Ahmad; Ingolf Cascorbi
Journal:  Eur J Clin Pharmacol       Date:  2011-10-20       Impact factor: 2.953

2.  High-resolution melt analysis to detect sequence variations in highly homologous gene regions: application to CYP2B6.

Authors:  Greyson P Twist; Roger Gaedigk; J Steven Leeder; Andrea Gaedigk
Journal:  Pharmacogenomics       Date:  2013-06       Impact factor: 2.533

Review 3.  Possible Susceptibility Genes for Intervention against Chemotherapy-Induced Cardiotoxicity.

Authors:  Xinyu Yang; Guoping Li; Tao Yang; Manke Guan; Na An; Fan Yang; Qianqian Dai; Changming Zhong; Changyong Luo; Yonghong Gao; Saumya Das; Yanwei Xing; Hongcai Shang
Journal:  Oxid Med Cell Longev       Date:  2020-10-13       Impact factor: 6.543
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.